Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Long-acting beta2-adrenergic agonist (LABA) and inhaled corticosteroid (ICS) combination for asthma

Indacaterol / Mometasone Furoate

Atectura Breezhaler

Dosage form
Tablet
Available strengths
150 mcg/80 mcg, 150 mcg/160 mcg, 150 mcg/320 mcg (indacaterol/mometasone furoate) per capsule
Drug class
Long-acting beta2-adrenergic agonist (LABA) and inhaled corticosteroid (ICS) combination for asthma
Common brand
Atectura Breezhaler

Clinical overview. Atectura Breezhaler combines indacaterol, a long-acting beta2-agonist, with the inhaled corticosteroid mometasone furoate, in a once-daily inhaled capsule for the maintenance treatment of asthma in patients 12 years of age and older. It comes in three strengths to match low, medium, or high inhaled corticosteroid needs and is not intended for relief of sudden asthma symptoms. Common side effects include headache, sore throat, and oral thrush, while serious risks include adrenal suppression, reduced bone density, and paradoxical bronchospasm.

Indication

Common therapeutic uses

  • Atectura Breezhaler is used as a once-daily maintenance treatment for asthma in adults and adolescents 12 years of age and older whose disease is not adequately controlled on an inhaled corticosteroid alone, or whose severity requires both a LABA and an ICS.
  • Atectura Breezhaler is not meant for patients who only occasionally need a fast-acting reliever inhaler or who are well controlled on an inhaled corticosteroid alone.
  • Atectura Breezhaler does not relieve sudden asthma symptoms and is not a rescue inhaler.

Pregnancy

Risk assessment and monitoring considerations

  • There is not enough human data on Atectura Breezhaler, indacaterol, or mometasone furoate in pregnancy to determine any drug-related risk.
  • Animal studies found that mometasone furoate increased the risk of birth defects, and reduced fetal survival and growth, when given to pregnant animals.
  • Atectura Breezhaler should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus, and poorly controlled asthma itself carries risks for both mother and baby.

Breastfeeding

Infant exposure considerations

  • It is not known whether indacaterol or mometasone furoate pass into human breast milk, though both have been found in the milk of nursing rats.
  • Other inhaled corticosteroids similar to mometasone furoate are known to pass into human milk.
  • The decision to use Atectura Breezhaler while breastfeeding should weigh the mother's need for asthma control against any possible effect on the nursing infant.

Geriatrics

Dosing and tolerability considerations

  • No dose adjustment is required in patients 65 years of age or older, although some older individuals may be more sensitive to its effects.

Pediatrics

Use in children and adolescents

  • Atectura Breezhaler is authorized for patients 12 years of age and older; its safety and effectiveness have not been established in children under 12.
  • Inhaled corticosteroids, including the mometasone furoate component, may slow growth velocity in children and adolescents, so growth should be monitored regularly.

Dosage & Administration

Practical dosing and administration

  • The recommended starting dose depends on how much inhaled corticosteroid the patient needs: 150/80 mcg once daily for a low corticosteroid dose, or 150/160 or 150/320 mcg once daily for a medium or high corticosteroid dose.
  • The maximum recommended dose is 150/320 mcg once daily.
  • No dose adjustment is required for kidney impairment.
  • No dose adjustment is required for mild or moderate liver impairment; in severe liver impairment, Atectura Breezhaler should be used only if the benefit outweighs the risk.
  • If a dose is missed, take it as soon as possible, but never take more than one dose in a day.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • There is limited experience with Atectura Breezhaler overdose in clinical studies.
  • An overdose is likely to cause exaggerated effects of its two components, such as a fast heart rate, tremor, palpitations, headache, nausea, vomiting, drowsiness, dangerous heart rhythms, changes in blood sugar or potassium, and suppression of the body's natural cortisol production.
  • Management of overdose includes general supportive care and symptomatic treatment; hospitalization may be needed in serious cases.
  • A cardioselective beta-blocker may be considered cautiously for severe cardiovascular effects, since it can also worsen bronchospasm.

Common side effects

Frequently reported tolerability concerns

  • Headache may occur.
  • Musculoskeletal pain, including back or neck pain, may occur.
  • Sore or irritated throat may occur.
  • Hoarseness or voice changes (dysphonia) may occur.
  • Oral or throat yeast infection (thrush) may occur.
  • Increased blood sugar may occur.
  • Common cold-like symptoms (nasopharyngitis) may occur.
  • Muscle cramps or spasms may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Severe allergic reactions, including swelling of the face, lips, tongue, or throat, hives, or rash, can occur.
  • Sudden worsening of breathing (paradoxical bronchospasm) can occur immediately after use.
  • Long-term use of the corticosteroid component can suppress the body's natural adrenal hormone production, which may be unmasked during illness, injury, or surgery.
  • Reduced bone density can develop with long-term inhaled corticosteroid use, particularly in patients with other risk factors for osteoporosis.
  • Eye problems, including glaucoma, cataracts, and a rare condition called central serous chorioretinopathy, can develop with long-term corticosteroid use.
  • A rare condition involving inflammation of blood vessels (eosinophilic granulomatosis with polyangiitis) has been associated with inhaled corticosteroid use, usually when oral steroids are being reduced.
  • Slowed growth in children and adolescents can occur with long-term inhaled corticosteroid use.
  • Increased susceptibility to infections, including a more severe course of chickenpox or measles, can occur with corticosteroid use.
  • Fast or irregular heartbeat can occur, related to the beta-agonist component.
  • Seek urgent medical attention for sudden worsening of breathing after using the inhaler, chest pain, a fast or irregular heartbeat, or signs of a severe allergic reaction.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with heart disease, including coronary artery disease, recent heart attack, or abnormal heart rhythms.
  • Use with caution in patients with diabetes, since blood sugar should be monitored more closely, especially when starting treatment.
  • Use with caution in patients with active or past tuberculosis, or other chronic or untreated infections.
  • Use with caution in patients with glaucoma or a family history of glaucoma, and monitor eye pressure periodically.
  • Use with caution in patients at risk for reduced bone density, such as those who smoke, are postmenopausal, or take other bone-thinning medications.
  • Use with caution in patients switching from an oral corticosteroid to Atectura Breezhaler, since this transition should be done gradually under medical supervision.
  • Use with caution in patients predisposed to low blood potassium levels or seizure disorders.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients hypersensitive to indacaterol, mometasone furoate, or any ingredient in the formulation.

Drug interactions

Clinically relevant combinations

  • Beta-blockers, including some eye drops, can weaken the effect of Atectura Breezhaler and should generally be avoided; if needed, a cardioselective beta-blocker may be used cautiously.
  • Other medicines that prolong the QT interval, including certain antidepressants and monoamine oxidase inhibitors, may increase the risk of dangerous heart rhythms when combined with Atectura Breezhaler.
  • Methylxanthine drugs, corticosteroids, and non-potassium-sparing diuretics may increase the risk of low blood potassium when combined with Atectura Breezhaler.
  • Other medicines containing a long-acting beta-agonist should not be used together with Atectura Breezhaler.
  • Strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, and ritonavir, can increase blood levels of both indacaterol and mometasone furoate, raising the risk of side effects including adrenal suppression.

Food interactions

Meal-related administration

  • Atectura Breezhaler can be taken with or without food, and its inhaled capsules are not affected by meals.

Time of administration

Practical scheduling

  • Atectura Breezhaler should be inhaled once daily at the same time each day, and can be taken at any time of day regardless of meals.
  • Rinse your mouth with water after each dose, without swallowing, to help reduce the risk of oral thrush.

Storage

Product handling

  • Store Atectura Breezhaler capsules at room temperature between 15°C and 30°C, protected from moisture and light.
  • Keep capsules in their blister packaging and remove them only immediately before use.

Patient take-away

Key counselling points for a quick closing summary

  • Atectura Breezhaler is a once-daily inhaled combination medicine used for ongoing asthma control, not for sudden asthma attacks.
  • Always keep a fast-acting rescue inhaler on hand for sudden symptoms, since Atectura Breezhaler works slowly and is not meant for immediate relief.
  • Rinse your mouth after each use to help prevent oral thrush.
  • Never swallow the capsules; they must be used only with the Atectura Breezhaler inhaler device.

References

Source material and product information

  1. Health Canada Product Monograph — Indacaterol / Mometasone Furoate

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.